ArcticZymes Technologies - Regulatory Filings 2021

ArcticZymes Technologies Launches SAN HQ 2.0

Tromsø, Norway, 30[th] June 2021 - ArcticZymes Technologies ASA (OSE: AZT)

announces the launch of the second generation of its SAN HQ enzyme

ArcticZymes Technologies´ Salt Active Nuclease High Quality (SAN HQ) enzyme has

achieved significant penetration in the viral vector manufacturing space in the

last 5 years. Viral vectors are used in therapeutic applications such as

vaccines and gene therapies. SAN HQ treatment is used in the downstream

purification of viral vectors to remove contaminating DNA.

The second generation of the enzyme, SAN HQ 2.0, has been optimised for wider

compatibility with downstream processes used in biomanufacturing. In particular,

SAN HQ 2.0 offers improved resolution in several chromatographic techniques,

thereby simplifying the separation of the nuclease from the target product post

treatment. ArcticZymes anticipates that SAN HQ 2.0 will increase the Company's

reach within the viral vector space and provide new opportunities in recombinant

protein production.

The product will be commercially available from late Q3 2021.

For more information, please contact:

CEO, Jethro Holter Tel: +47 46 85 91 46

CFO, Børge Sørvoll Tel: +47 95 29 01 87

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the

development, manufacturing and commercialization of novel recombinant enzymes

for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

Listed on the Oslo Stock Exchange since 2005 originally under the [Biotec]

ticker, as Biotec Pharmacon. The company rebranded as ArcticZymes Technologies

in 2020 under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at

the SIVA Innovation Centre.

ArcticZymes Technologies' IP and capabilities are protected via a large

portfolio of patents.

For more information, please visit the website: www.arcticzymes.com.

AI assistant